28 July 2020: OIA response: annual funding volumes of trastuzumab

28 July 2020

Dear [name and contact details withheld] 

REQUEST FOR INFORMATION 

Thank you for your request dated 30 June under the Official Information Act 1982 (OIA) for information relating to trastuzumab. You asked for: 

“the most recent data on annual volumes of trastuzumab, ideally split by vial size but if not then in total mg per annum.” 

The data you have requested is listed in the table below as volumes of trastuzumab funded. The data for 2020 is current up until the end of May 2020. 

Chemical name

Formulation

Brand name

Calendar year

Units – number of vials

Trastuzumab

Inj 440 mg vial

Herceptin

2015

1,811.09

Trastuzumab

Inj 440 mg vial

Herceptin

2016

1,912.3

Trastuzumab

Inj 440 mg vial

Herceptin

2017

1,789.49

Trastuzumab

Inj 440 mg vial

Herceptin

2018

1,413.27

Trastuzumab

Inj 440 mg vial

Herceptin

2019

1,401.4

Trastuzumab

Inj 440 mg vial

Herceptin

2020

722.85

Trastuzumab

Inj 150 mg vial

Herceptin

2015

6,960.36

Trastuzumab

Inj 150 mg vial

Herceptin

2016

7,893.77

Trastuzumab

Inj 150 mg vial

Herceptin

2017

8,702.97

Trastuzumab

Inj 150 mg vial

Herceptin

2018

8,017.33

Trastuzumab

Inj 150 mg vial

Herceptin

2019

8,844.92

Trastuzumab

Inj 150 mg vial

Herceptin

2020

3,074.1

 

Chemical name

Formulation

Brand name

Calendar year

Units – mg

Trastuzumab

Inj 1 mg for ECP

Baxter

2015

1,824,241.5

Trastuzumab

Inj 1 mg for ECP

Baxter

2016

2,017,107

Trastuzumab

Inj 1 mg for ECP

Baxter

2017

2,004,816

Trastuzumab

Inj 1 mg for ECP

Baxter

2018

2,322,975

Trastuzumab

Inj 1 mg for ECP

Baxter

2019

2,019,095

Trastuzumab

Inj 1 mg for ECP

Baxter

2020

753,092

[ECP = Extemporaneously Compounded Preparations]

We trust that this information answers your queries.  We are making our information more freely available, so we will now publish selected OIA responses (excluding personal details) on our website.  Please get in touch with us if you have any questions about this.


Yours sincerely

 

Rachel Read
Manager, Policy and Government Services